The FDA on August 6, 2024, approved VORANIGO®, an Isocitrate DeHydrogenase-1 (IDH1) and Isocitrate DeHydrogenase-2 (IDH2) inhibitor, for adult and pediatric patients 12 years and older with Grade 2 Astrocytoma or Oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection. VORANIGO® is a product of Servier Pharmaceuticals, LLC.
Bottom Ad
Advertisement
Subscribe
